Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report)’s stock price shot up 3.8% on Tuesday . The company traded as high as 0.28 and last traded at 0.27. 292,900 shares changed hands during trading, a decline of 52% from the average session volume of 615,489 shares. The stock had previously closed at 0.26.
Perspective Therapeutics Stock Performance
The company has a market cap of $75.75 million, a price-to-earnings ratio of -3.00 and a beta of 1.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.72 and a quick ratio of 3.59.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last released its quarterly earnings data on Friday, August 11th. The company reported -0.04 earnings per share for the quarter, missing analysts’ consensus estimates of -0.03 by -0.01. The company had revenue of 2.09 million for the quarter, compared to analysts’ expectations of 2.61 million. Perspective Therapeutics had a negative net margin of 239.46% and a negative return on equity of 19.46%. As a group, sell-side analysts forecast that Perspective Therapeutics, Inc. will post -0.16 EPS for the current year.
Institutional Trading of Perspective Therapeutics
Perspective Therapeutics Company Profile
Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.
- Five stocks we like better than Perspective Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- GSK is a remedy for the winter investment blahs
- Dividend Payout Ratio Calculator
- After blowout earnings, Integer may be headed to new highs
- What Are Dividends? Buy the Best Dividend Stocks
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.